Tesamorelin
A synthetic analogue of growth hormone-releasing hormone with a trans-3-hexenoic acid modification. FDA-approved for HIV-related lipodystrophy and studied for its selective effects on visceral adipose tissue.
For laboratory and in vitro research purposes only. Not for human consumption.
What is Tesamorelin?
Tesamorelin is a synthetic analogue of the full 44-amino acid sequence of growth hormone-releasing hormone, with a trans-3-hexenoic acid modification at the N-terminus to extend its plasma stability. It received FDA approval as Egrifta for HIV-associated lipodystrophy — making it the only GHRH analogue with FDA approval and providing one of the most robust human clinical datasets available for any GHRH-class compound. Researchers use it to study visceral fat reduction, GH/IGF-1 axis dynamics, and body composition mechanisms.
fda approved ghrh analogue.
the strongest clinical record.
Tesamorelin is the only GHRH analogue with FDA approval, earning it as Egrifta for HIV-related visceral fat accumulation. Large-scale randomized controlled trials make it one of the most well-characterized GHRH compounds for researchers who require a solid human evidence base.
How Tesamorelin works in research models
Tesamorelin is a full-length GHRH analogue (44 amino acids) with a trans-3-hexenoic acid conjugated to the N-terminus to increase plasma stability. It binds pituitary GHRH receptors to stimulate pulsatile GH release, which in turn drives IGF-1 production. The downstream effect is selective lipolysis — particularly of visceral adipose tissue (VAT).
selective visceral fat reduction.
via the gh/igf-1 axis.
Tesamorelin drives selective reduction of visceral adipose tissue through GH/IGF-1 axis activation. Its selectivity for visceral fat — with minimal effects on subcutaneous fat — makes it a precise tool for body composition research.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.
N Engl J Med · 2007 · PMID: 17634458
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.
Lancet HIV · 2019 · PMID: 31285187
The approved human clinical dose is 2 mg subcutaneous once daily. Preclinical animal studies have used weight-adjusted equivalents. Reconstitute with sterile water and inject immediately. Store reconstituted solution at 4°C and use within 24 hours.
You ask, we answer.
Tesamorelin is a synthetic analogue of the full 44-amino acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification that significantly extends its plasma half-life compared to native GHRH (approximately 30 minutes vs 7 minutes).
Sermorelin is GHRH(1-29) — the 29-amino acid N-terminal fragment. Tesamorelin is the full 44-amino acid GHRH sequence. Both stimulate pituitary GH release, but Tesamorelin has a more extensively studied human clinical profile and longer stability.
Egrifta is the FDA-approved pharmaceutical form of Tesamorelin, approved in 2010 for reducing excess abdominal fat in HIV-positive patients with lipodystrophy. It is the first and only GHRH analogue to receive FDA approval, providing clinical pharmacokinetic, efficacy, and safety data.
The selectivity for visceral adipose tissue (VAT) appears to be related to the distribution of GH receptors and metabolic activity differences between fat depots. Visceral fat is more metabolically active and more responsive to GH-driven lipolysis than subcutaneous fat. In clinical trials, Tesamorelin reduced VAT by 15-20% with minimal effects on subcutaneous fat.
Research Use Only
All Rowan Peptides products are intended strictly for laboratory and in vitro research purposes. They are not approved by the FDA and are not intended for human consumption, veterinary use, or any therapeutic application. By purchasing, you agree to our Terms of Service and Indemnity Waiver. Rowan Peptides LLC operates as a chemical supplier only.
Good product. The Slim Stack saves money if you're doing AOD-9604 anyway, which I figured out after this order. Grab that instead.
Running this alongside AOD-9604. Tesamorelin's FDA approval for lipodystrophy gives it a research profile that's easy to trust and Rowan's sourcing is clean. 2mg vial, proper lyophilization, COA inside.
The stabilized GHRH modification makes tesamorelin one of the more interesting compounds for visceral fat research. Ordered 3 vials. All came with matching lot numbers in the COA database. That's the kind of supply chain transparency you want.
Write a Review